Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
BMS reports phase 3 win in multiple myeloma
With the study continuing to evaluate survival endpoints, it is unclear whether the drugmaker has the evidence needed to seek approval from the FDA.
Nick Paul Taylor
Sep 23, 2025 8:20am
Roche reports phase 3 breast cancer victory for oral SERD
Sep 22, 2025 7:25am
QL Biopharm links monthly GLP-1 to incumbent-rivaling efficacy
Sep 18, 2025 7:20am
Regeneron's ultrarare disease phase 3 hits, teeing up filings
Sep 17, 2025 9:31am
Lilly rounds out orforglipron data ahead of obesity filings
Sep 17, 2025 9:00am
Roivant reports phase 3 autoimmune win for ex-Pfizer asset
Sep 17, 2025 7:00am